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Abstract
Bacterial vaginosis (BV) is a common problem in women that is characterized by a
decreased colonization of Lactobacillus in the vagina. Such conditionmay lead to various
complications including endometritis, pelvic inflammatory disease, miscarriage, preterm
birth, chorioamnionitis, premature rupture of the membrane, postpartum endometritis
and increasing failure of in vitro fertilization. Treating BV using antimicrobials is
somehow effective but often causes recurrences and antibiotic resistance. This paper
examines the use of probiotic consisting of Lactobacillus spp. for the treatment of BV by
conducting a systematic review of research articles published in online databases. After
the review process, there are 18 articles with a total of 2,442 women as participants
selected in this present report. There are six mechanisms involved in BV treatment
using probiotic; i.e., (1) competition mechanism with pathogens, (2) stabilization of
mucin layer, (3) production of antibacterial substances for killing and preventing the
colonization of pathogenic bacteria, (4) reduction of the vaginal pH, (5) stimulation of
the immune system, and (6) restoration of vaginal homeostasis. Previous studies were
evaluated and the findings suggest that probiotics are better than antimicrobials in
treating BV due to the absence of reported side effects. In addition, giving probiotics
especially Lactobacillus sp. can be a better therapy of BV.
1. Introduction
Urogenital infections can degrade the quality of women’s life [1]. Bacterial vaginosis
(BV) is a urogenital infection affecting an estimate of 20%–42% of women in repro-
ductive age [2, 3]. A more specific study states that in women aged 14-49 years, the
prevalence of BV reaches 29.2% [4]. A study conducted on 492 Indonesian women
has reported that the minimum prevalence of BV is 30.7% with risk factors including
age over 40 years and couples who do not perform circumcision or circumcision pro-
cesses [5]. Bacterial vaginosis is a condition characterized by a decreasing number of
microbiota Lactobacillus spp. and followed by an increasing number of other bacteria
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such as Gardnerella vaginalis, Atopobium vaginae, Prevotella spp., Mobilucus spp. and
Mycoplasma hominis. Bacterial vaginosis is also defined as a polymicrobial syndrome
characterized by abnormal vaginal discharge in women. In this condition, Lactobacillus
especially produces hydrogen peroxide (H202) [6].
Complications of BV include endometritis, an increase in the incidence of sexually
transmitted infections such as human immunodeficiency virus (HIV) infection, miscar-
riage, preterm birth, chorioamnionitis, premature rupture of membranes, and postpartal
endometritis. In women who undergo in-vitro fertilization, BV decreases the chance of
embryo implantation thereby increasing the failure in the development of the pregnancy
[2, 7].
Metronidazole is the most common antibiotics used for BV therapy. However, recent
studies showed that when metronidazole is used for short term therapy (up to 30 days),
the cure rate is low [8] and can lead to >50% until 69% of recurrence rates in 6-12
months after the cessation of therapy [9]. The side effects of metronidazole include
gastrointestinal disorders (e.g., nausea, vomiting, leukopenia, and metallic taste in the
mouth when administered orally). We conducted a systematic review to examine the use
of probiotics for BV therapy in comparison with conventional therapy.
2. Methods
2.1. Search strategy and study selection
Study articles were searched in PubMed, Science Direct, Web of Science, Springer Link
and the Cochrane Database. The key words included probiotic AND bacterial vagi-
nosis, probiotic AND randomized controlled trial, probiotic AND placebo, probiotic AND
metronidazole.
2.2. Assesment of study quality
The inclusion criteria were randomized controlled trials (RCTs), probiotic therapy given
is Lactobacillus spp. or metronidazole and placebo regimens, or both. The subjects
included women of reproductive age who were treated for ≥5 days. The studies were
reviewed if the cases of lost to follow-up were <20%. Bacterial vaginosis was diagnosed
based on Nugent score of ≥7 – 10 which represent the number of airy morphotype
organisms per microscopic field; the organisms included lactobacillus, mobiluncus, and
Gardnella vaginalis (given score 4 if there are >30 organisms per microscopic field) [10].
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Another criteria used for diagnosing BV is Amsel criteria. According to Amsel criteria,
someone is considered suffer from bacterial vaginosis when three of these symptoms
are present: (i) the acidity or pH > 4.7; (ii) vaginal discharge color is gray or white; (iii) the
release of fish odor when the whiff test is done; (iv) there are clue cells on microscopic
examinationwith saline solution [11, 12]. This review reported articles published in English
from 1994 until 2017.
3. Results
The review process and the number of articles found is shown in Figure 1.
3
gh
Figure 1: Flow diagram of the study.
4. Discussion
Antimicrobial therapy for BV can cause various side effects especially for long-term use
but will cause recurrences when the duration of therapy is too short. This phenomenon
promotes researchers to look back to the natural vaginal defense process relying on the
Lactobacillus spp. which control and kill pathogens causing bacterial vaginosis such as
Gardnerella vaginalis. Three studies show that oral probiotic gave better therapeutic
effect rather than metronidazole [12]. However, another study shows that the therapeutic
effect of 500 mg of metronidazole is better than probiotic [13]. This contradicting results
might be due to the number of BV cases is inequal for each group. Previously, the authors
of this present paper have conducted a meta-analysis and found that the administration
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of probiotics is as effective as metronidazole therapy with the combination of probiotics
and metronidazole is a better choice rather than antimicrobial and for preventing BV
recurrences [14, 15].
4.1. Lactobacillus sp mechanism to combat BV
Probiotics against BV through various mechanisms, including competition with
pathogens in the process of erythrocytes adherence [16], stabilization of mucin layer
and prevention of the growth of pathogenic bacteria [17], and producing antibacte-
rial substances such as bacteriocin, reuterin, reutericyclin, and hydrogen peroxide.
Bacteriocin is antibiotics synthezised from probiotic bacteria that are active against
pathogenic bacteria [18]. Lactobacillus reuteri produces heavy antibiotics components
but tends to have a wide spectrum of resistance to reuterin and reutericyclin. Both of
them have a benefit in decreasing the levels of urease in the feces so as to suppress
the growth of bacteria and inhibit the growth of pathogens [19]. Lactobacillus can
produce hydrogen peroxide as a result of its high affinity with oxygen compared to other
species. The effects of H2O2 on pathogenic bacteria depend on the oxidizing ability of
the bacterial cell wall. Hydrogen peroxide works alongside with other organic acids
to overcome pathogenic bacteria such as Listeria monocytogenes, Bacillus cereus,
Bacillus subtilis, Yersinia enterocolitica, Escherichia coli, Pseudomonas aeruginosa,
Salmonella typhimurium, Gardnerela vaginalis and Klebsiella pneumoniae [20].
In addition, organic acids with antibacterial properties, including acetic acid and lactic
acid, are produced as a result of hexose fermentation by probiotic bacteria. Different
species of probiotic bacteria will affect the levels and types of organic acids produced.
The acid diffusion through the probiotic bacteria membrane cells which are increasingly
hydrophobic or directly into the cell, stimulate the release of hydrogen ions that acidify
the cytoplasm of pathogenic bacteria. The acidity of acetic acid is stronger than lactic
acid; thus, more potent for inhibiting pathogenic bacteria and fungi. The acidity causes
the collapse of the electrochemical proton gradient resulting in bacterial death [21].
Probiotics will suppress the inflammatory reaction, normalize mucosal permeability,
and improve the immunologic barrier, especially the IgA response. This can stimulate
the body’s immune system [22, 23]. Combination of probiotic and antimicrobial therapies
after previously administered antimicrobial therapy can improve Lactobacillus coloniza-
tion in the vagina and the addition of Lactobacilli can rebuild vaginal homeostasis. This
can explain why women treated with probiotics have a lower and longer recurrence rate
[8]. All of these mechanisms explain why the results of comparison between probiotic
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and placebo from eight studies show that probiotics are more effective than placebo
[2,3, 22-27] and one study shows the contrary [28].
4.2. The recommended dosage
The evidence has shown that probiotics can be an alternative therapy for bacterial
vaginosis. Important information required is the optimum dosage and the composition
of probiotics with the best therapeutic results. There are two studies comparing the
dosage with standard administered 108 CFU Lactobacillus [29, 30]. The results showed
that twice daily dosage gave better therapeutic effects than once daily dosage but the
results are not statistically significant.
4.3. The risk factors of BV
An increasing number of pathogens that cause BV and a decrease in the number of
vaginal normal flora that can become natural protective of the vagina can be caused
by various factors including the levels of estrogen and progesterone, psychological
and environmental factors, age and contraception. The menstrual cycle that women
experience every month induces estrogen secretion. This hormone is very influential
on BV occurence because a decrease in estrogen level has been linked to a decrease
numbers of Lactobacillus in the vagina [31]. Estrogen also plays a role in supporting
the proliferation process of the vaginal epithelium. In addition to estrogen, during the
menstrual process there is also the release of progesterone. This hormone has a role
in supporting the cytolysis process of epithelial cells, where glycogen is re-used by
Lactobacillus and othermicrobiota thatmetabolize and convert it to glucose andmaltose
which will further be converted to lactic acid which makes the vagina have a level of
acidity ranging from 3.8 - 4.4 under normal conditions [32, 33].
Psychological and environmental factors that can increase the likelihood of BV include
sexual activity and smoking habits. Health conditions of sexual partners especially cir-
cumcision can reduce the risk of BV. It is not known with certainty the magnitude of
genetic influences on the incidence of BV, but genetic polymorphisms have been known
to interfere with the innate immune system, even allelic polymorphisms in gene introns,
especially in interleukin-1 cytokines (IL1RN2) are associated with increased vaginal acid-
ity (pH) and followed by a decrease in the amount of Lactobacillus spp. in the vagina
[34-36].
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Women inmenarche age has an unstable amount of Lactobacillus. However, after get-
ting the menstrual cycle as explained above,the hormones estrogen and progesterone
released during menstruation contribute to the survival of Lactobacillus. Women who
enter menopause, post menopause or those who no longer have a normal menstrual
cycle are very likely to suffer from BV [34]. The choice of contraceptive method has
been shown to change the amount of microbiota in the vagina. Research conducted on
331 women who used cervical cap and diaphragm-spermicide experienced an increase
in the number of colonization from Escherichia coli in contrast to women who use pill
contraception who were found to have a decrease in the number of colonization of
microbiota such as Escherichia coli and Candida spp. [37].
5. Conclusion
The results of this systematic review recommend probiotic therapy twice daily in a con-
centration of 8x108 CFU of Lactobacillus spp. because this therapy is more effective
than metronidazole. Another advantage of probiotic is it does not have side effects for
therapy and prevention of BV.
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